

WHO WE ARE: MISSION & VISION

Rafael Pharmaceuticals is a privately held, clinical-stage, cancer metabolism therapeutics company.

MISSION: To develop highly selective, well tolerated, and highly effective anti-cancer agents, by targeting metabolic pathways in cancer cells, inhibiting pro cancer immune guardians and stimulating or preserving the anti-cancer immune system. Our goal is to transform care for patients with difficult to treat cancers.

VISION: Aspire to be a high growth, fully integrated cancer metabolism therapeutics leader focused on extending and improving the lives of patients with cancer.

CANCER METABOLISM STRATEGY

- Cohesive pipeline that targets the metabolic foundation for tumor growth, by hitting DNA replication inputs and mitochondria
- Targets metabolic processes specifically important to cancer cells
- Unique mode of mitochondrial targeting that is well tolerated with activity across wide variety of cancers
- Integrates the immune system
- Potential therapeutic options for a wide range of difficult to treat cancers
- Lead asset, devimistat has shown to have a large safety profile, enabling use in chronic dosing and in combination with current standards of care with minimal added toxicity

CPI-613® (DEVIMISTAT) & PIPELINE


- Devimistat, our lead drug is currently being evaluated in two phase 3 trials in first-line metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML) in combination with standard drug therapy. Both indications have been granted Fast Track Designations by the FDA
- Over 750 patients to date spanning multiple tumor types have received devimistat in 20 ongoing or completed clinical trials
- Devimistat has demonstrated positive efficacy and safety signals in phase I clinical trials in multiple cancer types:

Cancer	Pancreatic (PDAC)	Acute Myeloid Leukemia (AML)	T-Cell Lymphoma
Treatment	devimistat + modified FOLFIRINOX	devimistat + cytarabine + mitoxantrone	devimistat + bendamustine
Patient Population	first-line metastatic	relapsed or refractory (≥50 years)	relapsed or refractory
Objective Response Rate	61%	52%	75%
Median Overall Survival (months)	19.9	10.4	9.2

- Devimistat has been granted US orphan drug designation for pancreatic cancer, AML, myelodysplastic syndromes (MDS), peripheral T-cell lymphoma, Burkitt lymphoma and clear cell sarcoma. Devimistat also has orphan drug designations for pancreatic cancer and AML in the EU.
- Novel chemical class, composition of matter and formulation protected to 2028 across US, Canada, EU, Australia, Israel and major markets of Asia (China, Hong Kong, Japan, South Korea, Taiwan)
- Several new drug/chemical entities (NCE's) targeting multiple tumor types are currently in discovery or preclinical studies

A Pipeline For Sustainable Growth

CPI-613® (devimistat) A Pipeline in a Molecule



- Two Phase 3 Pivotal Trials already recruited ~700 patients in metastatic pancreatic cancer and r/r AML
- 20 Ongoing or Completed Clinical Trials in Multiple Hematological Malignancies & Solid Tumors
- Rafael Pharmaceuticals entered into exclusive licensing agreement with Ono Pharmaceutical to accelerate clinical development and commercialization of devimistat in Japan and select Asian countries

EXPERIENCED LEADERSHIP TEAM

Sanjeev Luther, *President & CEO*

Robert G. L. Shorr, PhD, DIC, *Chief Scientist/Co-founder*

Timothy S. Pardee, MD, PhD, *Co-Chief Medical Officer*

Mike Hu, PhD, *Chief Development Officer*

Shuhe Wang, VP, *Head of Global Drug Safety & Pharmacovigilance*

Wendy McDermott, *Chief People Officer*

Paul Bingham PhD, VP, *Research*

Jehan Rowlands, Pharm.D., VP, *Regulatory Affairs*

Deepak Tiwari, VP, *CMC*

Mike Stelmah, VP, *QA/CQA*

LEADING ADVISORY BOARD MEMBERS

SCIENTIFIC ADVISORY BOARD

Chi Van Dang, MD, PhD

Dafna Bar-Sagi, PhD

MEDICAL ADVISORY BOARD

Philip A. Philip, MD, PhD, FRCP

Jorge Eduardo Cortes, MD

Ariela Noy, MD

Josep Taberner MD, PhD

Eric Van Cutsem, MD, PhD